Plasma thromboxane and prostacyclin are linear related and increased in patients presenting with acute myocardial infarction.

Journal Article

The role of prostanoids in patients with ischemic heart disease including acute myocardial infarction (AMI) has been recognized. However, there is very limited knowledge of the baseline TXB2 and 6-keto-PGF1a plasma levels in patients with AMI before therapy has been administered. We compared plasma levels of TXB2 and 6-keto-PGF1a by enzyme immunoassay in 18 AMI patients before thrombolysis, with those of 13 healthy controls. Plasma levels of TXB2 (319.78+/-16.50 pg/ml) and 6-keto-PGF1a (536.72+/-56.71 pg/ml) were heterogeneous, but significantly higher in the AMI patients than in controls (175.92+/-17.29 pg/ml and 192.08+/-26.11 pg/ml, respectively). In some patients, long-term aspirin therapy mildly inhibits baseline prostanoid levels, however, limited data prevents us from further speculations on this issue. Although, the contributions by prostanoids to the pathogenesis of AMI have been well proposed, their plasma concentrations are not uniformly elevated, and it is still unclear whether the resultant changes are indicative of clinically meaningful effects.

Full Text

Duke Authors

Cited Authors

  • Gurbel, PA; Murugesan, SR; Lowry, DR; Serebruany, VL

Published Date

  • July 1999

Published In

Volume / Issue

  • 61 / 1

Start / End Page

  • 7 - 11

PubMed ID

  • 10477035

International Standard Serial Number (ISSN)

  • 0952-3278

Language

  • eng

Conference Location

  • Scotland